Shanghai Aohua Photoelectricity Endoscope News

Australian and Chinese Endoscopy (688212): Short-term tenders slow down and continue to be optimistic about AQ-300 emissions

中信建投證券Sep 14 07:16

Australian and Chinese Endoscopy (688212): Steady revenue growth is expected to accelerate in the second half of the year

華創證券Sep 13 07:51

Aohua Endoscopy (688212): Performance is in line with expectations, equity payments affect apparent profit

Sep 3 13:46

Aohua Endoscopy (688212): Revenue is under pressure in the short term, and new product release can be expected

Aug 27 20:56

Aohua Endoscopy (688212): Performance is in line with expectations, and tenders are expected to improve in the second half of the year

Aug 27 13:16

Aohua Endoscopy (688212): 2024H1 performance is in line with expectations and is expected to resume bidding in the second half of the year

Aug 26 16:16

Aohua Endoscopy (688212): The company's performance is in line with expectations and accelerates product entry into overseas markets

Aug 23 16:56

Aohua endoscopy (688212): rapid release of the AQ-300 can be expected for overseas expansion

Jun 1 00:00

Aohua Endoscopy (688212): Revenue increased 35% in the first quarter of 2024, AQ300 continued to gain strength

May 6 16:16

Australian and Chinese Endoscopy (688212): Achieving relatively rapid revenue growth, net interest rates are under pressure in the short term

May 4 00:00

Aohua Endoscopy (688212): 1Q24 revenue is in line with expectations and maintain 2024 full-year guidelines

May 1 10:56

Australia China Endoscopy (688212) 2024 Quarterly Report Review: Revenue Growth Continues in the Context of High Base Stock Payments Interferes with 2024Q1 Net Profit

Apr 30 00:00

Aohua Endoscopy (688212): Q1 revenue is in line with expectations and is still growing at a high base

Apr 29 00:00

Aohua Endoscopy (688212): 1Q24's revenue is growing rapidly

Apr 29 00:00

Pacific released a research report on April 23 stating that it gave Australian and Chinese endoscopy (688212.SH) a purchase rating. The main reasons for the rating include: 1) the gradual release of high-end endoscopes and the increase in the penetration

Zhitong FinanceApr 23 10:13

Aohua Endoscopy (688212): Performance is in line with expectations, AQ-300 achieves rapid release

Apr 19 14:51

Guoxin Securities released a research report on April 15 stating that it maintains the Australian and Chinese endoscopy (688212.SH) purchase rating. The main reasons for the rating include: 1) excellent performance in 2023, with rapid improvement in insta

Zhitong FinanceApr 15 14:05

Aohua Endoscopy (688212): Outstanding performance, increased sales and R&D investment

Apr 15 13:36

Southwest Securities released a research report on April 12 stating that it gave Australian and Chinese endoscopy (688212.SH) a purchase rating, and the target price was 67.2 yuan. The main reasons for the rating include: 1) gross margin rebounded sharply

Zhitong FinanceApr 12 21:49

Aohua Endoscopy (688212) 2023 Report Review: Sales of high-end products continue to break through, and performance grows rapidly

Apr 12 18:31